Dr. Susan Kirshner received an M.Sc. from University of North Carolina School of Public Health in the field of environmental toxicology. She received a Ph.D. in Immunology from the Weizmann Institute of Science, where she worked on the development of an immunomodulatory peptide for the treatment of Myasthenia gravis. Dr. Kirshner’s post-doctoral training was at the National Cancer Institute in the area of transcriptional regulation of MHC class I genes. Dr. Kirshner worked both in the government and industry before joining the Office of Biotechnology Products at the US FDA 18 years ago. She is currently the Review Chief for the Division of Biotechnology Research and Review, OBP/ FDA.